Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Primary CNS Lymphoma in Myasthenic on Long-term Azathioprine
J NeuroOncol 74:91-92, Finelli,P.F., 2005
Management of Multiple Sclerosis
NEJM 337:1604-1611, Rudick,R.A.,et al, 1997
Risk of Cancer from Azathioprine Therapy in Multiple Sclerosis:A Case-Control Study
Neurol 46:1607-1612, Confavreux,C.,et al, 1996
Lambert-Eaton Myasthenic Syndrome:Clinical Diagnosis,Immune-Mediated Mechanisms,and Update on Therapies
Ann Neurol 37:S63-S73, Sanders,D.B., 1995
Myasthenia Gravis
NEJM 330:1797-1810, Drachman,D.B., 1994
Long-Term Safety of Azathioprine Therapy in Multiple Sclerosis
Neurol 43:831-833, Amato,M.P.,et al, 1993
The Efficacy of Azathiorpine in Relapsing-Remitting Multiple Sclerosis
Neurol 41:20-25, Goodkin,D.E.,et al, 1991
Overview of Azathioprine Treatment in Multiple Sclerosis
Lancet 338:1051-1055, Yudkin,P.L.,et al, 1991
A Placebo-Controlled, Randomized, Clinical Trial of Azathioprine with & without Methylpred in MS
Neurol 39:1018-1026, Ellison,G.W.,et al, 1989
Cyclosporine Vs. Azathioprine in the Long-Term Treatment of Multiple Sclerosi-Results of German Multicenter Study
Ann Neurol 23:56-63, Kappos,L.,et al, 1988
Immunotherapy of Multiple Sclerosis
Ann Neurol 23:211-223, Weiner,H.L.&Hafler,D.A., 1988
Double-Masked Trial of Azathioprine in Multiple Sclerosis
British and Dutch Multiple Sclerosis Azathioprine Trial Group, Lancet 2:179-1831988., , 1988
Double-Blind Controlled Trial Of Immunosuppresion In The Treatment Of Multiple Sclerosis:Final Report
Lancet 2:351-354, Mertin,J.,et al, 1982